Clinical Trials Browser

Interventional × durvalumab × Thoracic × Clear all

NCT02888743 2026-03-18

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04092283 2026-03-18

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06732401 2026-03-18

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Phase 3 Suspended

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05198830 2026-03-17

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06667908 2026-03-16

CONVERGE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780137 2026-03-16

MK-6070-002

Phase 1/2 Recruiting

Small Cell Lung Carcinoma

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT07391670 2026-03-12

IMFINZI-subQ

Phase 1 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Phase 2 Recruiting

Lung Neoplasms

NCT07459634 2026-03-10

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05696782 2026-03-06

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase 2 Active not recruiting

301 enrolled 15 charts

Lung Cancer Metastatic

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT06890598 2026-03-03

SUNRAY-02

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT06992609 2026-03-02

ALBORAN

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT04602533 2026-02-27

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Phase 2 Active not recruiting

Lung Neoplasms

NCT06773910 2026-02-27

TIGOS-LS

Phase 2 Recruiting

Limited Stage Small Cell Lung Cancer

NCT07005128 2026-02-27

DeLLphi-312

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT05211895 2026-02-23

PACIFIC-8

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07361497 2026-02-19

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07149363 2026-02-17

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT03819465 2026-02-11

MAGELLAN

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03965468 2026-02-09

CHESS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06898957 2026-02-05

(DeLLphi-310)

Phase 1 Recruiting

Small Cell Lung Carcinoma

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Phase 1 Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT07339059 2026-01-30

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05925530 2026-01-29

MDT-BRIDGE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05206812 2026-01-27

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung